Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS

• Published in: Internal Medicine Vol. 61; no. 22; pp. 3459 - 3462
• Main Authors: Adachi, Eisuke, Saito, Makoto, Koga, Michiko, Tsutsumi, Takeya, Yotsuyanagi, Hiroshi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 15.11.2022; Japan Science and Technology Agency
• Subjects: Acquired immune deficiency syndrome; Acquired Immunodeficiency Syndrome; AIDS; Antibodies, Monoclonal - therapeutic use; Antibodies, Viral; Case Report; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 Drug Treatment; HIV; HIV/AIDS; Human immunodeficiency virus; Humans; Immune reconstitution; Immunodeficiency; Immunotherapy; Inflammation; Internal medicine; Monoclonal antibodies; monoclonal antibody therapy; passive immunity; Patients; persistent viral shedding; prolonged COVID-19; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; sotrovimab; HIV/AIDS; prolonged COVID-19; passive immunity; sotrovimab; monoclonal antibody therapy; persistent viral shedding
• ISSN: 0918-2918; 1349-7235; 1349-7235
• DOI: 10.2169/internalmedicine.0485-22

Persistent viral shedding or prolonged coronavirus disease 2019 (COVID-19) symptom is one of unresolved problem in immunocompromised individuals. We herein report an HIV/AIDS patient with Pneumocystis jirovecii pneumonia and prolonged COVID-19, possibly due to immune reconstitution inflammatory syndrome. His viral shedding and COVID-19 symptoms persisted for 39 days but were promptly resolved following sotrovimab monoclonal antibody therapy. This case suggests that prolonged COVID-19 and persistent viral shedding due to severe cellular immunodeficiency can occur in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron infection and that sotrovimab is effective in the treatment of prolonged COVID-19 caused by omicron/BA.1.